Loading...
Header Logo
Keywords
Last Name
Institution

Gary E Raskob

TitleDean
InstitutionUniversity of Oklahoma Health Sciences Center
DepartmentPublic Health Office of Dean
Address801 NE 13th St
Oklahoma City OK 73104-5005
Phone405/271-2232
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    McMaster University, Hamilton, ONMSc1985Clinical Epidemiology
    University of Oklahoma, Oklahoma City, OKPhD1999Pharmaceutical Sciences

    Collapse Research 
    Collapse research activities and funding
    U54GM104938     (JAMES, JUDITH A)Sep 1, 2013 - Jun 30, 2018
    NIH
    Oklahoma Shared Clinical and Translational Resources
    Role: Co-Investigator

    U50DD000899     (RASKOB, GARY E.)Apr 1, 2012 - Mar 31, 2015
    CDC/NCBDD
    ACTIVE SURVEILLANCE FOR VENOUS THROMBOEMBOLISM IN A RACIALLY DIVERSE POPULATION
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Kraaijpoel N, van Es N, Raskob GE, Büller HR, Carrier M, Zhang G, Lin M, Grosso MA, Di Nisio M. Risk Scores for Occult Cancer in Patients with Venous Thromboembolism: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2018 Jun 04. PMID: 29864787.
      View in: PubMed
    2. Kraaijpoel N, van Es N, Bleker SM, Brekelmans MPA, Eerenberg ES, Middeldorp S, Cohen AT, Raskob GE, Büller HR. Clinical Impact and Course of Anticoagulant-Related Major Bleeding in Cancer Patients. Thromb Haemost. 2018 Jan; 118(1):174-181. PMID: 29304537.
      View in: PubMed
    3. Vanassche T, Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MPA, Chen CZ, Cohen AT, Grosso MA, Medina AP, Mercuri MF, Winters SM, Zhang G, Weitz JI, Raskob GE, Büller HR. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial. Thromb Res. 2018 02; 162:7-14. PMID: 29248859.
      View in: PubMed
    4. Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, Büller HR. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 02 15; 378(7):615-624. PMID: 29231094.
      View in: PubMed
    5. Medina A, Raskob G, Ageno W, Cohen AT, Brekelmans MPA, Chen CZ, Grosso MA, Mercuri MF, Segers A, Verhamme P, Vanassche T, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study. Thromb Haemost. 2017 12; 117(12):2406-2414. PMID: 29212128.
      View in: PubMed
    6. Bleker SM, Brekelmans MPA, Eerenberg ES, Cohen AT, Middeldorp S, Raskob G, Büller HR. Clinical impact of major bleeding in patients with venous thromboembolism treated with factor Xa inhibitors or vitamin K antagonists. An individual patient data meta-analysis. Thromb Haemost. 2017 Oct 05; 117(10):1944-1951. PMID: 28816341.
      View in: PubMed
    7. Spyropoulos AC, Raskob GE. New paradigms in venous thromboprophylaxis of medically ill patients. Thromb Haemost. 2017 Aug 30; 117(9):1662-1670. PMID: 28640324.
      View in: PubMed
    8. Blumenthal DS, Raskob G. The Value of Prevention Research Centers: Breaking New Ground in Prevention Research. Am J Prev Med. 2017 Mar; 52(3S3):S214-S215. PMID: 28215366.
      View in: PubMed
    9. Di Nisio M, Raskob G, Büller HR, Grosso MA, Zhang G, Winters SM, Cohen A. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists. Thromb Haemost. 2017 04 03; 117(4):784-793. PMID: 28151543.
      View in: PubMed
    10. Ageno W, Casella IB, Han CK, Raskob GE, Schellong S, Schulman S, Singer DE, Kimura K, Tang W, Desch M, Goldhaber SZ. RE-COVERY DVT/PE: Rationale and design of a prospective observational study of acute venous thromboembolism with a focus on dabigatran etexilate. Thromb Haemost. 2017 01 26; 117(2):415-421. PMID: 27853808.
      View in: PubMed
    11. Bleker SM, Cohen AT, Büller HR, Agnelli G, Gallus AS, Raskob GE, Weitz JI, Curto M, Sisson M, Middeldorp S. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial. Thromb Haemost. 2016 Nov 30; 116(6):1159-1164. PMID: 27583312.
      View in: PubMed
    12. Brekelmans MP, Ageno W, Beenen LF, Brenner B, Buller HR, Chen CZ, Cohen AT, Grosso MA, Meyer G, Raskob G, Segers A, Vanassche T, Verhamme P, Wells PS, Zhang G, Weitz JI. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 Sep; 3(9):e437-45. PMID: 27570090.
      View in: PubMed
    13. Verhamme P, Wells PS, Segers A, Ageno W, Brekelmans MP, Cohen AT, Meyer G, Grosso MA, Raskob G, Weitz JI, Zhang G, Buller H. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial. Thromb Haemost. 2016 09 27; 116(4):747-53. PMID: 27440518.
      View in: PubMed
    14. Raskob GE, van Es N, Segers A, Angchaisuksiri P, Oh D, Boda Z, Lyons RM, Meijer K, Gudz I, Weitz JI, Zhang G, Lanz H, Mercuri MF, Büller HR. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. Lancet Haematol. 2016 Aug; 3(8):e379-87. PMID: 27476789.
      View in: PubMed
    15. Key NS, Khorana AA, Mackman N, McCarty OJ, White GC, Francis CW, McCrae KR, Palumbo JS, Raskob GE, Chan AT, Sood AK. Thrombosis in Cancer: Research Priorities Identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Res. 2016 07 01; 76(13):3671-5. PMID: 27527638.
      View in: PubMed
    16. Wells PS, Prins MH, Levitan B, Beyer-Westendorf J, Brighton TA, Bounameaux H, Cohen AT, Davidson BL, Prandoni P, Raskob GE, Yuan Z, Katz EG, Gebel M, Lensing AWA. Long-term Anticoagulation With Rivaroxaban for Preventing Recurrent VTE: A Benefit-Risk Analysis of EINSTEIN-Extension. Chest. 2016 Nov; 150(5):1059-1068. PMID: 27262225.
      View in: PubMed
    17. Wendelboe AM, Raskob GE. Global Burden of Thrombosis: Epidemiologic Aspects. Circ Res. 2016 Apr 29; 118(9):1340-7. PMID: 27126645.
      View in: PubMed
    18. Aelion CM, Airhihenbuwa CO, Alemagno S, Amler RW, Arnett DK, Balas A, Bertozzi S, Blakely CH, Boerwinkle E, Brandt-Rauf P, Buekens PM, Chandler GT, Chang RW, Clark JE, Cleary PD, Curran JW, Curry SJ, Diez Roux AV, Dittus R, Ellerbeck EF, El-Mohandes A, Eriksen MP, Erwin PC, Evans G, Finnegan JR, Fried LP, Frumkin H, Galea S, Goff DC, Goldman LR, Guilarte TR, Rivera-Gutiérrez R, Halverson PK, Hand GA, Harris CM, Healton CG, Hennig N, Heymann J, Hunter D, Hwang W, Jones RM, Klag MJ, Klesges LM, Lahey T, Lawlor EF, Maddock J, Martin WJ, Mazzaschi AJ, Michael M, Mohammed SD, Nasca PC, Nash D, Ogunseitan OA, Perez RA, Perri M, Petersen DJ, Peterson DV, Philbert M, Pinto-Martin J, Raczynski JM, Raskob GE, Rimer BK, Rohrbach LA, Rudkin LL, Siminoff L, Szapocznik J, Thombs D, Torabi MR, Weiler RM, Wetle TF, Williams PL, Wykoff R, Ying J. The US Cancer Moonshot initiative. Lancet Oncol. 2016 05; 17(5):e178-80. PMID: 27301041.
      View in: PubMed
    19. Liles NW, Page EE, Liles AL, Vesely SK, Raskob GE, George JN. Diversity and severity of adverse reactions to quinine: A systematic review. Am J Hematol. 2016 May; 91(5):461-6. PMID: 26822544.
      View in: PubMed
    20. Brekelmans MP, Bleker SM, Bauersachs R, Boda Z, Büller HR, Choi Y, Gallus A, Grosso MA, Middeldorp S, Oh D, Raskob G, Schwocho L, Cohen AT. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists. Thromb Haemost. 2016 07 04; 116(1):155-61. PMID: 27010092.
      View in: PubMed
    21. Raskob G, Ageno W, Cohen AT, Brekelmans MP, Grosso MA, Segers A, Meyer G, Verhamme P, Wells PS, Lin M, Winters SM, Weitz JI, Büller HR. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. Lancet Haematol. 2016 May; 3(5):e228-36. PMID: 27132697.
      View in: PubMed
    22. Raskob G, Wendelboe AM. Global public awareness of venous thromboembolism: reply. J Thromb Haemost. 2016 05; 14(5):1111-2. PMID: 26866426.
      View in: PubMed
    23. Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost. 2016 06 02; 115(6):1240-8. PMID: 26842902.
      View in: PubMed
    24. Raskob GE, Gallus AS, Sanders P, Thompson JR, Agnelli G, Buller HR, Cohen AT, Ramacciotti E, Weitz JI. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016 Apr; 115(4):809-16. PMID: 26661288.
      View in: PubMed
    25. Grosse SD, Nelson RE, Nyarko KA, Richardson LC, Raskob GE. The economic burden of incident venous thromboembolism in the United States: A review of estimated attributable healthcare costs. Thromb Res. 2016 Jan; 137:3-10. PMID: 26654719; PMCID: PMC4706477 [Available on 01/01/17].
    26. van Es N, Di Nisio M, Bleker SM, Segers A, Mercuri MF, Schwocho L, Kakkar A, Weitz JI, Beyer-Westendorf J, Boda Z, Carrier M, Chlumsky J, Décousus H, Garcia D, Gibbs H, Kamphuisen PW, Monreal M, Ockelford P, Pabinger I, Verhamme P, Grosso MA, Büller HR, Raskob GE. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. Thromb Haemost. 2015 Nov 25; 114(6):1268-76. PMID: 26271200.
      View in: PubMed
    27. Wendelboe AM, McCumber M, Hylek EM, Buller H, Weitz JI, Raskob G. Global public awareness of venous thromboembolism. J Thromb Haemost. 2015 Aug; 13(8):1365-71. PMID: 26084415.
      View in: PubMed
    28. Wendelboe AM, Campbell J, McCumber M, Bratzler D, Ding K, Beckman M, Reyes N, Raskob G. The design and implementation of a new surveillance system for venous thromboembolism using combined active and passive methods. Am Heart J. 2015 Sep; 170(3):447-54.e18. PMID: 26385027; PMCID: PMC4598067.
    29. Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, Raskob GE, Segers A, Verhamme P, Weitz JI. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med. 2015 Jan 15; 372(3):232-40. PMID: 25482425; PMCID: PMC4367537.
    30. Rosendaal FR, Raskob GE. On World Thrombosis Day. Lancet. 2014 Nov 08; 384(9955):1653-4. PMID: 25319500.
      View in: PubMed
    31. Rosendaal FR, Raskob GE. On World Thrombosis Day. Lancet. 2014 Nov 08; 384(9955):1653-4. PMID: 25473673.
      View in: PubMed
    32. Raskob GE, Angchaisuksiri P, Blanco AN, Buller H, Gallus A, Hunt BJ, Hylek EM, Kakkar A, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014 Nov; 34(11):2363-71. PMID: 25304324.
      View in: PubMed
    33. Raskob GE, Angchaisuksiri P, Blanco AN, Büller H, Gallus A, Hunt BJ, Hylek EM, Kakkar TL, Konstantinides SV, McCumber M, Ozaki Y, Wendelboe A, Weitz JI. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost. 2014 Oct; 40(7):724-35. PMID: 25302681.
      View in: PubMed
    34. Raskob GE. Oral anticoagulants: new and improved. Blood. 2014 Sep 18; 124(12):1851-2. PMID: 25606628.
      View in: PubMed
    35. Prins MH, Lensing AW, Bauersachs R, van Bellen B, Bounameaux H, Brighton TA, Cohen AT, Davidson BL, Decousus H, Raskob GE, Berkowitz SD, Wells PS. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013 Sep 20; 11(1):21. PMID: 24053656; PMCID: PMC3850944.
    36. Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013 Oct 10; 369(15):1406-15. PMID: 23991658.
      View in: PubMed
    37. Raskob GE. Importance of subsegmental pulmonary embolism. Blood. 2013 Aug 15; 122(7):1094-5. PMID: 23950170.
      View in: PubMed
    38. Raskob G, Büller H, Prins M, Segers A, Shi M, Schwocho L, van Kranen R, Mercuri M. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013 Jul; 11(7):1287-94. PMID: 23574579.
      View in: PubMed
    39. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013 Aug 29; 369(9):799-808. PMID: 23808982.
      View in: PubMed
    40. Nicolaides AN, Fareed J, Kakkar AK, Comerota AJ, Goldhaber SZ, Hull R, Myers K, Samama M, Fletcher J, Kalodiki E, Bergqvist D, Bonnar J, Caprini JA, Carter C, Conard J, Eklof B, Elalamy I, Gerotziafas G, Geroulakos G, Giannoukas A, Greer I, Griffin M, Kakkos S, Lassen MR, Lowe GD, Markel A, Prandoni P, Raskob G, Spyropoulos AC, Turpie AG, Walenga JM, Warwick D. Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol. 2013 Apr; 32(2):111-260. PMID: 24402349.
      View in: PubMed
    41. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 02 21; 368(8):699-708. PMID: 23216615.
      View in: PubMed
    42. Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012 Apr 05; 366(14):1287-97. PMID: 22449293.
      View in: PubMed
    43. Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials. J Bone Joint Surg Br. 2012 Feb; 94(2):257-64. PMID: 22323697.
      View in: PubMed
    44. Berger RM, Beghetti M, Humpl T, Raskob GE, Ivy DD, Jing ZC, Bonnet D, Schulze-Neick I, Barst RJ. Clinical features of paediatric pulmonary hypertension: a registry study. Lancet. 2012 Feb 11; 379(9815):537-46. PMID: 22240409; PMCID: PMC3426911.
    45. Büller HR, Gallus AS, Pillion G, Prins MH, Raskob GE. Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority trial. Lancet. 2012 Jan 14; 379(9811):123-9. PMID: 22130488.
      View in: PubMed
    46. Boutitie F, Pinede L, Schulman S, Agnelli G, Raskob G, Julian J, Hirsh J, Kearon C. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials. BMJ. 2011 May 24; 342:d3036. PMID: 21610040; PMCID: PMC3100759.
    47. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010 Dec 23; 363(26):2487-98. PMID: 21175312.
      View in: PubMed
    48. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010 Dec 23; 363(26):2499-510. PMID: 21128814.
      View in: PubMed
    49. Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, Spaeder J, Turpie AG. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost. 2010 Dec; 104(6):1150-7. PMID: 20886185.
      View in: PubMed
    50. Raskob G, Cohen AT, Eriksson BI, Puskas D, Shi M, Bocanegra T, Weitz JI. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. Thromb Haemost. 2010 Sep; 104(3):642-9. PMID: 20589317.
      View in: PubMed
    51. Frost AE, Badesch DB, Barst RJ, Benza RL, Elliott CG, Farber HW, Krichman A, Liou TG, Raskob GE, Wason P, Feldkircher K, Turner M, McGoon MD. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest. 2011 Jan; 139(1):128-37. PMID: 20558556.
      View in: PubMed
    52. van Doormaal FF, Cohen AT, Davidson BL, Decousus H, Gallus AS, Gent M, Piovella F, Prins MH, Raskob GE, Büller HR. Idraparinux versus standard therapy in the treatment of deep venous thrombosis in cancer patients: a subgroup analysis of the Van Gogh DVT trial. Thromb Haemost. 2010 Jul; 104(1):86-91. PMID: 20508907.
      View in: PubMed
    53. Raskob GE, Silverstein R, Bratzler DW, Heit JA, White RH. Surveillance for deep vein thrombosis and pulmonary embolism: recommendations from a national workshop. Am J Prev Med. 2010 Apr; 38(4 Suppl):S502-9. PMID: 20331950.
      View in: PubMed
    54. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010 Mar 06; 375(9717):807-15. PMID: 20206776.
      View in: PubMed
    55. Badesch DB, Raskob GE, Elliott CG, Krichman AM, Farber HW, Frost AE, Barst RJ, Benza RL, Liou TG, Turner M, Giles S, Feldkircher K, Miller DP, McGoon MD. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010 Feb; 137(2):376-87. PMID: 19837821.
      View in: PubMed
    56. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009 Aug 06; 361(6):594-604. PMID: 19657123.
      View in: PubMed
    57. Hull RD, Pineo GF, Brant R, Liang J, Cook R, Solymoss S, Poon MC, Raskob G. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med. 2009 Aug; 122(8):762-769.e3. PMID: 19635277.
      View in: PubMed
    58. Prins MH, Guillemin I, Gilet H, Gabriel S, Essers B, Raskob G, Kahn SR. Scoring and psychometric validation of the Perception of Anticoagulant Treatment Questionnaire (PACT-Q). Health Qual Life Outcomes. 2009 Apr 07; 7:30. PMID: 19348685; PMCID: PMC2686675.
    59. van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009 Apr; 101(4):762-9. PMID: 19350123.
      View in: PubMed
    60. McGoon MD, Krichman A, Farber HW, Barst RJ, Raskob GE, Liou TG, Miller DP, Feldkircher K, Giles S. Design of the REVEAL registry for US patients with pulmonary arterial hypertension. Mayo Clin Proc. 2008 Aug; 83(8):923-31. PMID: 18674477.
      View in: PubMed
    61. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, Misselwitz F, Raskob G, Schellong S, Segers A. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008 Sep 15; 112(6):2242-7. PMID: 18621928.
      View in: PubMed
    62. Stein PD, Sostman HD, Bounameaux H, Buller HR, Chenevert TL, Dalen JE, Goodman LR, Gottschalk A, Hull RD, Leeper KV, Pistolesi M, Raskob GE, Wells PS, Woodard PK. Challenges in the diagnosis of acute pulmonary embolism. Am J Med. 2008 Jul; 121(7):565-71. PMID: 18589050.
      View in: PubMed
    63. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008 Jun; 133(6 Suppl):454S-545S. PMID: 18574272.
      View in: PubMed
    64. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009 Jan; 24(1):1-9. PMID: 18534438.
      View in: PubMed
    65. Rathbun SW, Whitsett TL, Raskob GE. Exclusion of first-episode deep-vein thrombosis after-hours using D-dimer. Blood Coagul Fibrinolysis. 2007 Dec; 18(8):795-800. PMID: 17982322.
      View in: PubMed
    66. Lyman GH, Khorana AA, Falanga A, Clarke-Pearson D, Flowers C, Jahanzeb M, Kakkar A, Kuderer NM, Levine MN, Liebman H, Mendelson D, Raskob G, Somerfield MR, Thodiyil P, Trent D, Francis CW. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 01; 25(34):5490-505. PMID: 17968019.
      View in: PubMed
    67. Kirkpatrick A, Rathbun S, Whitsett T, Raskob G. Prevention of central venous catheter-associated thrombosis: a meta-analysis. Am J Med. 2007 Oct; 120(10):901.e1-13. PMID: 17904462.
      View in: PubMed
    68. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007 Sep 13; 357(11):1094-104. PMID: 17855670.
      View in: PubMed
    69. Buller HR, Cohen AT, Davidson B, Decousus H, Gallus AS, Gent M, Pillion G, Piovella F, Prins MH, Raskob GE. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med. 2007 Sep 13; 357(11):1105-12. PMID: 17855671.
      View in: PubMed
    70. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med. 2007 Jan; 120(1):72-82. PMID: 17208082.
      View in: PubMed
    71. Hull RD, Pineo GF, Brant RF, Mah AF, Burke N, Dear R, Wong T, Cook R, Solymoss S, Poon MC, Raskob G. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006 Dec; 119(12):1062-72. PMID: 17145251.
      View in: PubMed
    72. Miller A, Campbell I, Fennerty T, Raskob GE, Büller HR. Duration of warfarin in pulmonary embolism. Chest. 2006 Jul; 130(1):299; author reply 299-300. PMID: 16840417.
      View in: PubMed
    73. Hemenway D, Aglipay GS, Helsing KL, Raskob GE. Injury prevention and control research and training in accredited schools of public health: a CDC/ASPH assessment. Public Health Rep. 2006 May-Jun; 121(3):349-51. PMID: 16640161; PMCID: PMC1525291.
    74. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schünemann H. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. Chest. 2006 Jan; 129(1):174-81. PMID: 16424429.
      View in: PubMed
    75. Rathbun SW, Whitsett TL, Raskob GE. Negative D-dimer result to exclude recurrent deep venous thrombosis: a management trial. Ann Intern Med. 2004 Dec 07; 141(11):839-45. PMID: 15583225; PMCID: PMC1382279.
    76. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):287S-310S. PMID: 15383476.
      View in: PubMed
    77. Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 Sep; 126(3 Suppl):401S-428S. PMID: 15383479.
      View in: PubMed
    78. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004 Jun 01; 140(11):867-73. PMID: 15172900.
      View in: PubMed
    79. Rathbun SW, Whitsett TL, Vesely SK, Raskob GE. Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest. 2004 Mar; 125(3):851-5. PMID: 15006941; PMCID: PMC1215466.
    80. Sullivan SD, Davidson BL, Kahn SR, Muntz JE, Oster G, Raskob G. A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery. Pharmacoeconomics. 2004; 22(9):605-20. PMID: 15209529.
      View in: PubMed
    81. Henderson JN, Henderson LC, Raskob GE, Boatright DT. Chemical (VX) terrorist threat: public knowledge, attitudes, and responses. Biosecur Bioterror. 2004; 2(3):224-8. PMID: 15588061.
      View in: PubMed
    82. Raskob GE, Hirsh J. Controversies in timing of the first dose of anticoagulant prophylaxis against venous thromboembolism after major orthopedic surgery. Chest. 2003 Dec; 124(6 Suppl):379S-385S. PMID: 14668421.
      View in: PubMed
    83. Davidson BL, Sullivan SD, Kahn SR, Borris L, Bossuyt P, Raskob G. The economics of venous thromboembolism prophylaxis: a primer for clinicians. Chest. 2003 Dec; 124(6 Suppl):393S-396S. PMID: 14668423.
      View in: PubMed
    84. George JN, Raskob GE, Vesely SK, Moore D, Lyons RM, Cobos E, Towell BL, Klug P, Guthrie TH. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am J Hematol. 2003 Nov; 74(3):161-9. PMID: 14587042.
      View in: PubMed
    85. Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob G, van den Berg-Segers AE, Cariou R, Leeuwenkamp O, Lensing AW. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003 Oct 30; 349(18):1695-702. PMID: 14585937.
      View in: PubMed
    86. Blevins S, Edwards S, Raskob G. Helical computed tomography and magnet resonance imaging: diagnosis of pulmonary embolism in symptomatic patients. Curr Opin Hematol. 2003 Sep; 10(5):345-50. PMID: 12913788.
      View in: PubMed
    87. Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA, Raskob GE. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003 Jul 01; 102(1):60-8. PMID: 12637323.
      View in: PubMed
    88. Sullivan SD, Kahn SR, Davidson BL, Borris L, Bossuyt P, Raskob G. Measuring the outcomes and pharmacoeconomic consequences of venous thromboembolism prophylaxis in major orthopaedic surgery. Pharmacoeconomics. 2003; 21(7):477-96. PMID: 12696988.
      View in: PubMed
    89. Mustafa BO, Rathbun SW, Whitsett TL, Raskob GE. Sensitivity and specificity of ultrasonography in the diagnosis of upper extremity deep vein thrombosis: a systematic review. Arch Intern Med. 2002 Feb 25; 162(4):401-4. PMID: 11863471.
      View in: PubMed
    90. Lee A, Agnelli G, Büller H, Ginsberg J, Heit J, Rote W, Vlasuk G, Costantini L, Julian J, Comp P, van Der Meer J, Piovella F, Raskob G, Gent M. Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement. Circulation. 2001 Jul 03; 104(1):74-8. PMID: 11435341.
      View in: PubMed
    91. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 2001 Jan; 119(1 Suppl):108S-121S. PMID: 11157645.
      View in: PubMed
    92. Vesely S, Buchanan GR, Cohen A, Raskob G, George J. Self-reported diagnostic and management strategies in childhood idiopathic thrombocytopenic purpura: results of a survey of practicing pediatric hematology/oncology specialists. J Pediatr Hematol Oncol. 2000 Jan-Feb; 22(1):55-61. PMID: 10695823.
      View in: PubMed
    93. Levine MN, Raskob G, Landefeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest. 1998 Nov; 114(5 Suppl):511S-523S. PMID: 9822060.
      View in: PubMed
    94. Levine MN, Raskob G, Landefeld S, Hirsh J. Hemorrhagic complications of anticoagulant treatment. Chest. 1995 Oct; 108(4 Suppl):276S-290S. PMID: 7555182.
      View in: PubMed
    95. Stein PD, Hull RD, Raskob G. Risks for major bleeding from thrombolytic therapy in patients with acute pulmonary embolism. Consideration of noninvasive management. Ann Intern Med. 1994 Sep 01; 121(5):313-7. PMID: 8042819.
      View in: PubMed
    96. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med. 1993 Nov 04; 329(19):1370-6. PMID: 8413432.
      View in: PubMed
    97. Elliott CG, Suchyta M, Rose SC, Talbot S, Ford C, Raskob G, Hull R, Davidson B. Duplex ultrasonography for the detection of deep vein thrombi after total hip or knee arthroplasty. Angiology. 1993 Jan; 44(1):26-33. PMID: 8424582.
      View in: PubMed
    98. Levine MN, Hirsh J, Landefeld S, Raskob G. Hemorrhagic complications of anticoagulant treatment. Chest. 1992 Oct; 102(4 Suppl):352S-363S. PMID: 1395820.
      View in: PubMed
    99. Farrow L, Mungall D, Raskob G, Hull R. Predicting the daily prothrombin time response to warfarin. Ther Drug Monit. 1990 May; 12(3):246-9. PMID: 2349607.
      View in: PubMed
    100. Mungall D, Raskob G, Coleman R, Rosenbloom D, Ludden T, Hull R. Pharmacokinetics and dynamics of heparin in patients with proximal vein thrombosis. J Clin Pharmacol. 1989 Oct; 29(10):896-900. PMID: 2592581.
      View in: PubMed
    101. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1989 Feb; 95(2 Suppl):26S-36S. PMID: 2644101.
      View in: PubMed
    102. Fuller H, Raskob G, ter Keurs H, Hull R. The current status and future directions of impedance cardiography in ICU. Ann Biomed Eng. 1989; 17(5):483-94. PMID: 2610420.
      View in: PubMed
    103. Levine MN, Raskob G, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy. Chest. 1986 Feb; 89(2 Suppl):16S-25S. PMID: 3510826.
      View in: PubMed
    104. Levine MN, Raskob G, Hirsh J. Risk of haemorrhage associated with long term anticoagulant therapy. Drugs. 1985 Nov; 30(5):444-60. PMID: 3905338.
      View in: PubMed
    105. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, Turpie AG, McLoughlin D, Dodd P, Thomas M, Raskob G, Ockelford P. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med. 1982 Dec 30; 307(27):1676-81. PMID: 6755255.
      View in: PubMed
    106. Raskob G, Jay R, Hull R. Long-term anticoagulant therapy prevents recurrent venous thromboembolism. J R Soc Med. 1982 Apr; 75(4):289. PMID: 7069699; PMCID: PMC1437633.
    Raskob's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _